First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary

DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos' subsidiary Channel Pharmaceutical Corporation ("Channel") owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary.